Sales of Statin-Ezetimibe combination have risen sixfold

Hanmi, Yuhan, MSD, HK inno.N, and Daewoong grow rapidly

'Statin-Ezetimibe' combination, ￦470 billion last year, ↑ 21%

In the dyslipidemia treatment market, the combination drug market that combines 'Statin' and Ezetimibe' showed rapid growth.

 

Despite COVID-19 outbreak, the sales continued high.

 

In the past five years, sales have increased by six times.

 

Hanmi's Rosuzet and MSD's Atozet led the uptrend.

 

According to the drug research institute UBIST on the 25th, the prescription size of the lipid-regulator combination last year was ￦633.5 billion, an increase of 21.0% from the previous year.

 

The prescription market for lipid-regulating drugs increased by 10.2% and 15.1%, respectively, compared to the previous year in 2018 and 2019, but the growth trend further rose last year.

 

It showed the most remarkable growth among the major chronic disease treatment.

 

The prescription amount of Statin drugs used for the treatment of dyslipidemia last year was ￦1.97 trillion, an increase of 3.4% from the previous year.

 

The combination of calcium channel blocker (CCB) and angiotensin II receptor blocker (ARB), which are the most commonly used treatments for hypertension, recorded ￦8,113 billion last year, up 10.1% from the previous year.

 

The market for combination drugs that combines Ezetimibe and Statins showed remarkable growth.

 

Last year, the outpatient prescription for the combination drug Statin-Ezetimibe was ￦470.8 billion, an increase of 20.9% from the previous year.

 

It increased 55.6% in two years from ￦302.6 billion in 2018.

 

Compared to the ￦80 billion in 2015, the market size has expanded by 6 times over the past five years.

 

It is analyzed that Statin-Ezetimibe combination has an excellent effect in lowering LDL-C, and the preference is increasing because the drug price is not high.

 

It is analyzed that Statin-Ezetimibe combination has an excellent effect in lowering LDL-C, and the preference is increasing because the drug price is less than taking two drugs separately.

 

Simvastatin, Rosuvastatin, and Atorvastatin are sold in combination with Ezetimibe.

 

Sales of Rosuvastatin-Ezetimibe combination products rose the most.

 

Last year, the sales amount for the combination of Rosuvastatin and Ezetimibe was ￦352.9 billion, an increase of 25.7% from the previous year.

 

It increased 67.9% from two years ago, and continued high growth.

 

It increased by 159.1% from ￦136.6 billion in 2017, three years ago.

 

The Rosuvastatin-Ezetimibe combination market began in 2015 when Hanmi released Rosuzet.

 

It recorded ￦300 billion in sales after 5 years of entering the market.

 

Atorvastatin-Ezetimibe combination was also promoted.

 

Last year, the prescription amount for Atorvastatin-Ezetimibe was ￦74.7 billion, up 13.5% from the previous year.

 

From ￦44.5 billion in 2018, it grew 60.6% over the past two years.

 

Atozet is being sold jointly by MSD and Chong Kun Dang.

 

Currently, only one Atorvastatin-Ezetimibe combination sold is MSD's Atozet.

 

Sales of the Simvastatin-Ezetimibe combination were somewhat slow.

 

Last year, the prescription amount of Simvastatin-Ezetimibe was ￦44.2 billion, a 0.1% increase from the previous year.

 

MSD's Vytorin was the first to be released in the Statin-Ezetimibe combination market, but its growth is stagnating compared to other combination drugs.

 

Last year, Rosuzet's prescription performance was ￦99.1 billion, up 22.4% from the previous year.

 

Launched in late 2015, Rosuzet recorded ￦24.3 billion in prescriptions in 2016.

 

It showed high growth every year, including ￦41.5 billion in 2017, ￦61.2 billion in 2018, and ￦81 billion in 2019.

 

Last year, it ranked second in outpatient prescriptions among all drugs.

 

Hanmi secured the right to use Ezetimibe from MSD, the patent holder, and entered the market ahead of competitors, gaining an opportunity to preoccupy the market.

 

Considering the recent growth trend, it is also strong to exceed ￦100 billion in prescriptions this year.

 

Yuhan, HK inno.N, and Daewoong showed remarkable growth in the Rosuvastatin-Ezetimibe markets.

 

Yuhan's Rosuvamibe recorded a prescription amount of ￦54 billion last year.

 

In 2019, it rose 19.0% from ￦45.4 billion, exceeding ￦50 billion.

 

After recording a prescription amount of ￦7.2 billion in the first year of its release in 2016, Rosuvamibe has expanded its market influence every year, including ￦23.7 billion in 2017 and ￦35.4 billion in 2018.

 

HK inno.N's Rovazet recorded sales of ￦24.5 billion, up 17.1% from the previous year, and Daewoong's Crezet rose 35.2% from the previous year with a prescription performance of ￦19.8 billion last year.

 

In October of last year, Chong Kun Dang's self-developed Atorvastatin-Ezetimibe combination drug Lipilouzet was approved.

 

22 companies have been approved for the commissioned generic of Lipilouzet.

 

About 20 companies are preparing for Atojet's generic license.